Serafín Morales

6.6k total citations
134 papers, 1.6k citations indexed

About

Serafín Morales is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Serafín Morales has authored 134 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 103 papers in Oncology, 69 papers in Pulmonary and Respiratory Medicine and 45 papers in Cancer Research. Recurrent topics in Serafín Morales's work include Cancer Treatment and Pharmacology (58 papers), Advanced Breast Cancer Therapies (55 papers) and HER2/EGFR in Cancer Research (43 papers). Serafín Morales is often cited by papers focused on Cancer Treatment and Pharmacology (58 papers), Advanced Breast Cancer Therapies (55 papers) and HER2/EGFR in Cancer Research (43 papers). Serafín Morales collaborates with scholars based in Spain, United States and Germany. Serafín Morales's co-authors include José Baselga, Xavier Carbonell, Claire Barton, Parviz Ghahramani, Michael Clemens, Vernon Harvey, Michael Green, Noelia Martínez-Jáñez, Javier Cortés and Antonio Llombart‐Cussac and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Serafín Morales

131 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Serafín Morales Spain	16	1.2k	574	494	362	345	134	1.6k
Sònia Pernas Spain	20	1.1k 1.0×	447 0.8×	545 1.1×	413 1.1×	312 0.9×	109	1.6k
Akihiko Shimomura Japan	22	1.1k 0.9×	536 0.9×	537 1.1×	751 2.1×	331 1.0×	132	2.0k
Jennifer Eng‐Wong United States	20	1.5k 1.3×	711 1.2×	647 1.3×	245 0.7×	418 1.2×	59	2.0k
Zhimin Shao China	22	1.1k 1.0×	557 1.0×	557 1.1×	516 1.4×	290 0.8×	90	1.8k
Zhongsheng Tong China	20	1.2k 1.0×	754 1.3×	372 0.8×	324 0.9×	264 0.8×	105	1.7k
S. Tjulandin Russia	20	1.4k 1.2×	596 1.0×	724 1.5×	277 0.8×	357 1.0×	75	2.1k
Ying Fan China	23	1.1k 0.9×	513 0.9×	697 1.4×	542 1.5×	194 0.6×	120	1.7k
Nicola Battelli Italy	23	1.0k 0.9×	814 1.4×	553 1.1×	512 1.4×	180 0.5×	91	1.9k
Grazyna Liebérman United States	7	1.1k 0.9×	404 0.7×	238 0.5×	537 1.5×	268 0.8×	9	1.7k
G. Deplanque France	23	1.3k 1.1×	812 1.4×	542 1.1×	633 1.7×	221 0.6×	77	2.3k

Countries citing papers authored by Serafín Morales

Since Specialization

Citations

This map shows the geographic impact of Serafín Morales's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Serafín Morales with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Serafín Morales more than expected).

Fields of papers citing papers by Serafín Morales

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Serafín Morales. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Serafín Morales. The network helps show where Serafín Morales may publish in the future.

Co-authorship network of co-authors of Serafín Morales

This figure shows the co-authorship network connecting the top 25 collaborators of Serafín Morales. A scholar is included among the top collaborators of Serafín Morales based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Serafín Morales. Serafín Morales is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Oliveira, Mafalda, Eva Ciruelos, Guillermo Villacampa, et al.. (2025). Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial. Clinical Cancer Research. 32(3). 468–478.

Reiter, Matthew E., Catherine M. Hickey, Eduardo Palacios, et al.. (2025). Trends in nonbreeding shorebirds along the Pacific Americas Flyway. Ornithological applications. 128(1). 1–13. 1 indexed citations

García, José Manuel Pérez, María Gión, Manuel Ruíz‐Borrego, et al.. (2024). Prevention of sacituzumab govitecan (SG)-related neutropenia and diarrhea in patients (pts) with triple-negative or HR+/HER2- advanced breast cancer (ABC; PRIMED): A phase 2 trial.. Journal of Clinical Oncology. 42(16_suppl). 1101–1101. 11 indexed citations

Martínez-Jáñez, Noelia, Sònia Pernas, José Á. García-Sáenz, et al.. (2024). Abstract PO4-05-09: Phase I study of the FGFR inhibitor rogaratinib, fulvestrant and palbociclib in advanced hormone receptor-positive (HR+) breast cancer (BC) with FGFR1/2 amplification and/or overexpression (FGFR1/2+). Cancer Research. 84(9_Supplement). PO4–5. 2 indexed citations

Forget, Frédéric, Serafín Morales, Nuhad K. Ibrahim, et al.. (2024). AIPAC-003: A randomized, double-blind, placebo-controlled phase 3 trial testing eftilagimod alpha (soluble LAG-3) in patients with HER2-neg/low metastatic breast cancer receiving paclitaxel, following an open-label dose optimization.. Journal of Clinical Oncology. 42(16_suppl). TPS1125–TPS1125. 1 indexed citations

Freyer, Gilles, Noelia Martínez-Jáñez, Bożena Kukiełka-Budny, et al.. (2024). Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study. The Breast. 74. 103681–103681. 1 indexed citations

Pascual, Tomás, Mafalda Oliveira, Patricia Villagrasa, et al.. (2021). Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial. npj Breast Cancer. 7(1). 145–145. 8 indexed citations

Morales, Serafín, et al.. (2020). 230P Pathologic response to neoadjuvant therapy in HER2 positive/oestrogen receptor positive breast cancer patients. Annals of Oncology. 31. S333–S333. 1 indexed citations

Griguolo, Gaia, Garazi Serna, Tomás Pascual, et al.. (2020). 8P Characterization of immune microenvironment before and following anti-HER2 neoadjuvant therapy (NAT). Annals of Oncology. 31. S19–S19. 1 indexed citations

10.

Ciruelos, Eva, Dolores Isla, Rafael López‐López, et al.. (2019). Patient preference for oral chemotherapy in the treatment of metastatic breast and lung cancer. European Journal of Cancer Care. 28(6). e13164–e13164. 19 indexed citations

11.

Quintela-Fandiño, Miguel, Serafín Morales, Luís Manso, et al.. (2019). Randomized Phase 0/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast Cancer. Clinical Cancer Research. 26(1). 35–45. 32 indexed citations

12.

Blancas, Isabel, Elena Aguirre, Serafín Morales, et al.. (2018). Real-world data on the efficacy and safety of weekly oral vinorelbine in breast cancer patients previously treated with anthracycline or taxane-based regimens. Clinical & Translational Oncology. 21(4). 459–466. 10 indexed citations

13.

Minckwitz, Gϋnter von, Marco Colleoni, Hans‐Christian Kolberg, et al.. (2018). Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial. The Lancet Oncology. 19(7). 987–998. 84 indexed citations

14.

Prat, Aleix, Mafalda Oliveira, Lorena de la Peña, et al.. (2017). SOLTI-1303 PATRICIA: A phase II study of palbociclib and trastuzumab (with or without letrozole in ER+) in previously trastuzumab-pretreated, postmenopausal patients with HER2-positive metastatic breast cancer. Annals of Oncology. 28. v106–v107. 4 indexed citations

15.

Martín, Miguel, Moshe Inbar, Eva Carrasco, et al.. (2015). Phase III study of Palbociclib in combination with Exemestane vs. Capecitabine, in Hormonal Receptor (HR) positive/HER2 negative Metastatic Breast Cancer (MBC) patients with Resistance to non-steroidal Aromatase inhibitors (NSAI): PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006). Journal of Clinical Oncology. 1 indexed citations

16.

Aguirre, Elena, et al.. (2013). Severe thrombocytopenia related to long-term trastuzumab exposure.. PubMed. 99(1). e1–2. 2 indexed citations

17.

Sánchez‐Rovira, Pedro, Miguel Ángel Seguí, Antonio Llombart‐Cussac, et al.. (2013). Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response. Clinical & Translational Oncology. 15(10). 810–817. 9 indexed citations

18.

Morales, Serafín, Manuel Ramos, Miguel Méndez, et al.. (2003). Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study. Cancer Chemotherapy and Pharmacology. 53(1). 75–81. 19 indexed citations

19.

Morales, Serafín, et al.. (2001). Eficacia de la diálisis con albúmina en el tratamiento de los pacientes con insuficiencia hepática avanzada: primera experiencia en España con el sistema MARS. Nefrología. 21(4). 376–385. 3 indexed citations

20.

Vadell, Catalina, Miguel Ángel Seguí, Serafín Morales, et al.. (1998). Anticachectic Efficacy of Megestrol Acetate at Different Doses and Versus Placebo in Patients With Neoplastic Cachexia. American Journal of Clinical Oncology. 21(4). 347–351. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact